• Explore /
  • Poster
  • / Correlative biomarker analysis of sequential tumor biopsies in a ph I mode of action (MoA) study in neoadjuvant head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), with cetuximab (C) as reference.

Correlative biomarker analysis of sequential tumor biopsies in a ph I mode of action (MoA) study in neoadjuvant head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), with cetuximab (C) as reference.

Abstract Poster

Authors

null

Christoph Mancao

F. Hoffmann-La Roche Ltd, Basel, Switzerland

Christoph Mancao , Lilla Di Scala , Paul Delmar , Stéphane Temam , Jean-Charles Soria , James F. Spicer , Mark McGurk , Jean-Pierre Delord , Jerome Sarini , Niels Halama , Stefan Evers , Alexandre Passioukov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT01046266

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3035)

DOI

10.1200/jco.2013.31.15_suppl.3035

Abstract #

3035

Poster Bd #

13B

Abstract Disclosures

Similar Posters

First Author: Zhigong Wei

First Author: Niki Gavrielatou

First Author: Julie E. Bauman

First Author: Alexandra Leary